Any length of metformin vs none | Metformin ≤2 years vs none | Metformin >2 years vs none | ||||
aHR* | 95% CI | aHR* | 95% CI | aHR* | 95% CI | |
ND | 0.69 | 0.57 to 0.85 | 1.00 | 0.80 to 1.26 | 0.39 | 0.29 to 0.52 |
Dementia | 0.63 | 0.50 to 0.79 | 0.90 | 0.69 to 1.18 | 0.36 | 0.26 to 0.50 |
PD | 0.63 | 0.41 to 0.96 | 1.04 | 0.65 to 1.65 | 0.30 | 0.15 to 0.58 |
AD§ | 1.03 | 0.63 to 1.69 | 1.71 | 0.99 to 2.93 | 0.39 | 0.18 to 0.85 |
Mild cognitive impairment | 1.13 | 0.45 to 2.82 | 1.12 | 0.36 to 3.49 | 1.00 | 0.34 to 2.94 |
*Non-metformin treatment cohort was the reference group for adjusted HR (aHR) estimation.
AD, Alzheimer’s disease; ND, neurodegenerative disease; PD, Parkinson’s disease; PSW, propensity score weight.